login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
SCINAI IMMUNOTHERAPEUTICS LT (SCNI) Stock News
USA
- NASDAQ:SCNI -
US09073Q3039
-
ADR
1
USD
-0.09 (-8.68%)
Last: 11/13/2025, 8:00:02 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
SCNI Latest News, Press Relases and Analysis
All
Press Releases
a month ago - By: Scinai Immunotherapeutics Ltd.
Scinai Awarded Israel Innovation Authority Grant to Expand Fill-and-Finish CDMO Capabilities
2 months ago - By: Scinai Immunotherapeutics Ltd.
Scinai Reports Six-Month 2025 Financial Results Highlighting Continued CDMO Revenue Growth and Strengthened Balance Sheet
3 months ago - By: Benzinga
- Mentions:
NBY
AEMD
EVOK
THAR
...
12 Health Care Stocks Moving In Thursday's Pre-Market Session
3 months ago - By: Benzinga
- Mentions:
AEMD
MLSS
WINT
THAR
...
12 Health Care Stocks Moving In Wednesday's After-Market Session
a year ago - By: InvestorPlace
SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q2 2024
a year ago - By: BusinessInsider
SCNI Stock Earnings: Scinai Immunotherapeutics Reported Results for Q2 2024
4 months ago - By: Scinai Immunotherapeutics Ltd.
Scinai Announces New Peer-Reviewed Publication Supporting PC111 as a Disease-Modifying Therapy for Pemphigus and SJS/TEN
5 months ago - By: Scinai Immunotherapeutics Ltd.
Scinai Highlights Award-Winning Science Behind PC111 as Key Pincell Researcher Receives "Oscar of Italian Dermatology"
5 months ago - By: Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Receives Italian Government Clearance Under Golden Power Regulation for Potential Acquisition of Pincell S.r.l.
6 months ago - By: Scinai Immunotherapeutics Ltd.
Scinai Reports Q1 2025 Financial Results Highlighting Strong CDMO Revenue Momentum and Reduced Cash Burn
6 months ago - By: Scinai Immunotherapeutics Ltd.
Scinai Announces Annual Financial Results for 2024
8 months ago - By: Scinai Immunotherapeutics Ltd.
Scinai signs an option agreement to acquire rare disease company Pincell and its novel antibody for treating Severe Dermatological Conditions
8 months ago - By: Scinai Immunotherapeutics Ltd.
Scinai to Connect with Investors, Showcase its Innovative I&I pipeline and its Boutique cGMP Biologics CDMO during BIO-Europe Spring 2025
8 months ago - By: Scinai Immunotherapeutics Ltd.
SCINAI IMMUNOTHERAPEUTICS ANNOUNCES $10 MILLION STANDBY EQUITY PURCHASE AGREEMENT
10 months ago - By: Scinai Immunotherapeutics Ltd.
Scinai to Connect with Investors and Pharma Leaders at Upcoming Key US Conferences
a year ago - By: Scinai Immunotherapeutics Ltd.
Scinai Immunotherapeutics Establishes U.S. Subsidiary for CDMO Business Unit, Scinai Bioservices Inc.
a year ago - By: Scinai Immunotherapeutics Ltd.
Prof. Michael Schön, Director of Dermatology and Venereology at the University Medical Center Göttingen, Germany (UMG), Joins Scinai Immunotherapeutics' Scientific Advisory Board
a year ago - By: Scinai Immunotherapeutics Ltd.
Dr. Jonathan Sadeh, Former Senior Vice President of Immunology R&D at Bristol-Myers Squibb, Joins Scinai Immunotherapeutics' Scientific Advisory Board
a year ago - By: Scinai Immunotherapeutics Ltd.
Scinai Publishes Financial Results and Provides Business Update; Shareholders' Equity up from negative $7.3 million as of June 30, 2024, to positive $10 million
a year ago - By: Invezz
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) CEO Featured Guest on Latest Episode of BioMedWire Podcast
a year ago - By: Scinai Immunotherapeutics Ltd.
Scinai Regains Full Compliance with Nasdaq Listing Requirements
a year ago - By: Scinai Immunotherapeutics Ltd.
Scinai Announces Closing of Loan Restructuring Agreement with European Investment Bank Converting Approximately $29 million of Debt to Preferred Equity and Leaving Debt Balance of $273,000
a year ago - By: Invezz
BioMedNewsBreaks – Scinai Immunotherapeutics Ltd. (NASDAQ: SCNI) Enters Into $2M Investment Commitment Agreement with Its Largest Existing Shareholder
a year ago - By: Scinai Immunotherapeutics Ltd.
Scinai Announces Entering into $2 Million Private Equity Commitment Agreement with its largest Existing Shareholder
Please enable JavaScript to continue using this application.